Talon Therapeutics Inc (fka TLON)

[operating_line]

Each CVR holder(or their broker) is either on a CVR register with Corporate Stock Transfer Inc or another agent.

http://www.dailyfinance.com/2013/07/17/spectrum-pharmaceuticals-acquires-talon-therapeuti/

My concern is not where they are since they cannot be traded but how far off away the current sales level is from even the first milestone payment. Milestone payments for the CVRs are detailed here:
http://www.sec.gov/Archives/edgar/data/831547/000119312513445708/R21.htm

Given this payment schedule and ongoing clinical trials for Marqibo, it is unlikely any payments can occur soon. The following article suggests the first milestone is reached in 2018 according to the author's sales model.

http://www.thestreet.com/story/11989128/1/spectrum-can-generate-profits-from-misfit-cancer-drugs.html

I cannot remember how many CVRs were issued but if anyone has the figure off-hand, then you can work out a single CVR payment for the $5million payment. I am not throwing my CVRs away but not counting on getting my investment back. On the other hand, I have not been following the Marqibo R&D investments by Spectrum as the author suggests to see if there is more potential here. All we can do is wait otherwise.

The Spectrum report on Aug 6th shows Marqibo quarterly sales at 28% of the first milestone target if this sales level was sustained over any year:
MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $2.1 million

http://investor.sppirx.com/releases.cfm

If anyone sees potential in Marqibo developments, please share.